Latest news with #HealthVerity
Politico
3 days ago
- Health
- Politico
AI, the disruptor-in-chief
FORWARD THINKING Artificial intelligence is upending how industries function and it's coming for scientific research next. Rene Caissie, an adjunct professor at Stanford University, wants AI to conduct research. In 2021, he started a company, that lets public health departments, researchers and life sciences companies pose research questions and receive answers immediately. And, unlike many AI systems, Caissie told Ruth, the AI explains those answers by showing the data its results are based on. 'It used to be hard to do research,' he said, explaining that it takes a lot of time for researchers to get access to and organize data in order to answer basic scientific questions. Manual data analysis can also take months. The company is now partnering with HealthVerity, a provider of real-world health data, to build up its data sources. In turn, HealthVerity will offer Medeloop's research platform to its clients. The company has worked with the Food and Drug Administration, the National Institutes of Health, and the Centers for Disease Control and Prevention in the past. Caissie says the New York City Department of Health and Mental Hygiene is already using Medeloop's AI to run public health analyses. Why it matters: Public health departments receive huge amounts of data on human health from a variety of sources. But prepping that information and analyzing it can be onerous. Having access to a research platform like Medeloop could give public health departments and academic medical centers much faster insight into trends and in turn enable them to respond more quickly. How it works: Medeloop's AI is designed to think like a researcher. In a demo, Medeloop strategist John Ayers asked the bot how many people received a first-time autism diagnosis, broken down by age, race and sex, and what trends were visible with that data. He wanted the AI to only include people who had had interactions with a doctor for at least two years prior to diagnosis. The platform returned a refined query to improve results and a suggestion for what medical codes to use to identify the right patients for inclusion in the study. It delivered a trial design that looked at a cohort of 799,560 patients with new autism diagnoses between January 2015 and December 2024. Medeloop's AI showed that 70 percent of new autism diagnoses were for males. A monthly trends report found that, outside of a dip during the Covid-19 pandemic, new autism diagnoses have been on the rise, particularly among 5-11 year olds since 2019. Though Medeloop doesn't determine the cause of autism, the ease with which users can obtain answers could help speed up the pace of research. One of the platform's key innovations is its use of a federated network of data. Medeloop's new deal with HealthVerity will raise the platform's de-identified and secure patient records to 200 million. Notably, the data never leaves the health system, which increases security. Instead, Medeloop sends its AI to wherever the data is stored, analyzes it there and then returns the results to the platform. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Scientists are making cover art and figures for research papers using artificial intelligence. Now illustrators are calling them out, Nature's Kamal Nahas reports. Share any thoughts, news, tips and feedback with Danny Nguyen at dnguyen@ Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: Dannyn516.70, CarmenP.82, RuthReader.02 or ErinSchumaker.01. TECH MAZE Large language models like ChatGPT and Claude generate inferior mental health care treatment when presented with data about a patient's race, according to a study published this week in npj Digital Medicine. The findings: Researchers from Cedars-Sinai, Stanford University and the Jonathan Jaques Children's Cancer Institute tested how artificial intelligence would produce diagnoses for psychiatric patient cases under three conditions: race neutral, race implied and race explicitly stated using four models. They included the commercially available large language models ChatGPT, Claude and Gemini, as well as NewMes-15, a local model that can run on personal devices without cloud services. The researchers then asked clinical and social psychologists to evaluate the findings for bias. Most LLMs recommended dramatically different treatments for African American patients compared with others, even when they had the same psychiatric disorder and patient profile outside of race. The LLMs also proposed inferior treatments when they were made aware of a patient's race, either explicitly or implicitly. The biases likely come from the way LLMs are trained, the researchers wrote, and it's unclear how developers can mitigate those biases because 'traditional bias mitigation strategies that are standard practice, such as adversarial training, explainable AI methods, data augmentation and resampling may not be enough,' the researchers wrote. Why it matters: The study is one of the first evaluations of racial bias on psychiatric diagnoses across multiple LLMs. It comes as people increasingly turn to chatbots like ChatGPT for mental health advice and medical diagnoses. The results underscore the nascent technology's flaws. What's next: The study was small — only 10 cases were examined — which might not fully capture the consistency or extent of bias. The authors suggest that future studies could focus on a single condition with more cases for deeper analysis.
Yahoo
4 days ago
- Business
- Yahoo
HealthVerity and Medeloop Announce Strategic Partnership to Enhance Real-World Evidence Insights with AI-Driven Analytics
PHILADELPHIA and MENLO PARK, Calif., June 5, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange and Medeloop, innovators in AI-powered healthcare analytics, announced today an exclusive partnership designed to simplify and dramatically accelerate how pharmaceutical and biotech organizations, governments, and medical or public health researchers use real-world data for actionable insights and evidence generation. This powerful collaboration unites HealthVerity's extensive, privacy-compliant data ecosystem with Medeloop's cutting-edge AI Agent Analytics technology, enabling customers to uncover insights with unprecedented speed and transform vast, complex datasets into clear, actionable intelligence. Medeloop is a no-code analytics platform where a simple written research question is transformed into a full study, allowing users to rapidly generate insights without requiring programming expertise. Innovative researchers and analytics teams will benefit from unparalleled analytical power, accelerating the speed and impact of their research and decision-making processes. Through this partnership, Medeloop customers across Academic Medical Centers and Health Systems now have access to over 200 million de-identified patient records from HealthVerity's real-world data ecosystem, empowering them to ask their most complex research questions against research grade RWD at scale. Concurrently, HealthVerity pharmaceutical and biotech clients benefit from immediate integration of Medeloop's cutting-edge analytics technology, allowing them to generate deeper, more precise insights tailored specifically to their critical healthcare and research needs. "Our partnership with Medeloop represents a dramatic leap forward in real-world data analytics," said Andrew Kress, CEO of HealthVerity. "Previously, generating insights from real-world data required extensive teams and months of effort. Now, with this partnership combining our access to large-scale real-world data and Medeloop's leading-edge technology, we're enabling researchers and healthcare professionals to directly pose complex questions and receive powerful insights within minutes in a fully transparent, monitored, and human-guided fashion, fundamentally changing the pace and accessibility of data-driven healthcare research." René Caissie, CEO of Medeloop, added: "With HealthVerity, we're reshaping the future of healthcare analytics. By integrating the latest innovations in AI Agent Analytics with the richest real-world datasets available, we empower customers to rapidly achieve insights previously out of reach. This partnership accelerates scientific discovery, drives innovation, and ultimately helps save lives by enabling faster, more informed decisions that improve public health outcomes." Media Contacts: HealthVerityinfo@ MedeloopJohn W. Ayers, Ph.D., About HealthVerity HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making. About Medeloop Medeloop offers advanced, AI-powered analytics platforms designed to simplify and accelerate healthcare research, enabling pharmaceutical companies, healthcare providers, and researchers to rapidly derive actionable insights from complex real-world data by simply asking a question. View original content to download multimedia: SOURCE HealthVerity, Inc.
Yahoo
13-05-2025
- Business
- Yahoo
Premier, Inc. named as data source in HealthVerity Marketplace™ to expand real-world data access for life sciences research
Integration delivers high-value datasets including chargemaster, laboratory results and EMR data to accelerate clinical and commercial insights PHILADELPHIA, May 13, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced the addition of Premier, Inc. (NASDAQ: PINC) to HealthVerity Marketplace™, meaning life sciences organizations using HealthVerity Marketplace™ can now access Premier's high-quality, healthcare data to support research across the product lifecycle. HealthVerity Marketplace is the nation's largest verified healthcare and consumer data ecosystem, offering access to over 340 million de-identified individuals and enabling precise patient journey insights through the HIPAA-compliant linkage of diverse data types. With the addition of Premier data, HealthVerity Marketplace users can now use the platform to discover and license inpatient and outpatient data that supports evidence generation across a wide range of use cases, including market access, clinical development, and epidemiological research. Premier data available through HealthVerity Marketplace includes inpatient and outpatient electronic medical record (EMR) data. This opens pathways for the inclusion of de-identified, unstructured clinical notes. These enhancements will enable researchers to further validate clinical insights and strengthen study design with previously unavailable data. The Premier® Healthcare Database (PHD) is one of the most comprehensive electronic healthcare data repositories and the largest inpatient and outpatient chargemaster database. For nearly 25 years, it has served as a valuable source of RWD for the pharmaceutical and medical device industries, academic institutions, government agencies, and hospitals and health systems. Researchers using the PHD can analyze device and drug utilization with greater specificity, uncover trends in resource use and outcomes, and generate insights into care quality, safety and cost. Premier also offers EMR chart retrieval and review services that support regulatory-grade research and verification needs. "Our sharp focus on differentiated data, leading-edge research and clinical trials innovation helps drive speed to value," said Denise Juliano, Premier Applied Sciences Group Vice President. "Having the right data is critical for life sciences organizations aspiring to create meaningful change in healthcare. "Premier's partnership with HealthVerity securely links Premier® data with other real-world datasets, expanding on its longitudinal view of the patient journey that helps measure the effectiveness, quality and cost of therapies." "We are thrilled to officially welcome Premier as a named partner in HealthVerity Marketplace," said Andrew Kress, CEO of HealthVerity. "Premier's extensive, high-quality data adds substantial value for pharmaceutical manufacturers and healthcare innovators. These precise clinical insights are essential for therapeutic advancements and targeted patient care strategies." About HealthVerity HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making. To learn more, please visit HealthVerity contact:info@ About Premier, Inc. Premier, Inc. (NASDAQ: PINC) is a leading technology-driven healthcare improvement company, providing solutions to two-thirds of all healthcare providers in the U.S. Playing a critical role in the rapidly evolving healthcare industry, Premier unites providers, suppliers, payers and policymakers to make healthcare better with national scale, smarter with actionable intelligence and faster with novel technologies. Headquartered in Charlotte, N.C., Premier offers integrated data and analytics, collaboratives, supply chain solutions, consulting and other services in service of our mission to improve the health of communities. Please visit Premier's news and investor sites on as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier's blog for more information about the company. Premier contact:Public_Relations@ View original content to download multimedia: SOURCE HealthVerity, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-04-2025
- Business
- Yahoo
Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal
Recursion Pharmaceuticals recently announced a licensing agreement to integrate HealthVerity's extensive real-world data into its platforms. In the same week, Recursion reported significant advancements in its drug discovery initiatives and clinical studies, including dosing the first patient in a promising Phase 1 trial. Despite the broader market's flat performance over the past week, Recursion's stock price saw a 22% increase, suggesting that these developments reinforced investor confidence. The company's aim to accelerate drug discovery and clinical trials with enhanced data analytics may have added weight to this upward momentum. You should learn about the 4 possible red flags we've spotted with Recursion Pharmaceuticals (including 2 which don't sit too well with us). The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent developments at Recursion Pharmaceuticals, including the integration of HealthVerity's data and progress in drug trials, could significantly shift the company's revenue and earnings trajectory. These advancements might lead to enhanced efficiency in drug discovery and increased investor optimism. Over the past three years, however, Recursion's total shareholder return was a decline of 10.42%, highlighting the volatility and challenges in turning innovative efforts into consistent growth. Over the past year, Recursion underperformed relative to the broader US Biotechs industry, which posted a 6.3% decline. This contrast reveals potential discrepancies between the company's long-term strategies and the market's reception. Despite this underperformance, the recent 22% price surge following the announcements suggests renewed investor confidence in Recursion's future growth potential, though the company still faces significant developmental and financial hurdles. The ongoing innovations and strategic partnerships with major pharmaceutical entities are key drivers behind positive revenue and earnings forecasts. Analysts expect revenue to grow significantly per year, yet predict the company remains unprofitable for the next three years. The recent stock price increase remains below the consensus price target of US$8.71, indicating room for growth. However, achieving this target depends on the successful realization of outlined projects and transformation of pipeline developments into market-ready products. Gain insights into Recursion Pharmaceuticals' outlook and expected performance with our report on the company's earnings estimates. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:RXRX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Associated Press
16-04-2025
- Business
- Associated Press
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics. Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics. 'Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials,' said Andrew Kress, CEO of HealthVerity. 'By providing seamless access to the industry's most comprehensive and interoperable real-world data, we empower innovators like Recursion to make data-driven decisions that streamline clinical development.' Recursion's proprietary AI-driven approach relies on integrating diverse datasets and AI/ML models to identify novel insights into human biology and molecule design. The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites are positioned to meet enrollment goals. 'With the majority of the industry's time and resources focused on clinical trials, we see a significant opportunity to transform how clinical development is designed and executed,' said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. 'By integrating privacy-compliant real-world data from HealthVerity into Recursion OS, we are advancing our mission to optimize trial design through in silico simulations, accelerate recruitment through a patient-centric approach that includes underserved populations, and generate stronger evidence to inform development and regulatory decisions. By doing so, we are not only streamlining clinical development but also ensuring that we bring more impactful, life-changing treatments to patients faster and more efficiently' The HealthVerity approach to real-world data acquisition and governance ensures compliance with HIPAA and other regulatory frameworks while maintaining the highest standards of patient privacy. By combining data from the nation's largest healthcare data ecosystem, HealthVerity enables precise patient journey insights, supporting clinical development, regulatory submissions, and post-market studies. For more information, visit About HealthVerity HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making. About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine. Media Contact: HealthVerity [email protected] Recursion [email protected] View original content to download multimedia: SOURCE HealthVerity, Inc.
